Evaxion A/S
corporate_fare Company Profile
Evaxion A/S (NASDAQ:EVAX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 28 items for EVAX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-19, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 3 rated 8 or above. Recent SEC coverage for EVAX spans 6-K.
Recent high-impact activity:
- Evaxion Refocuses on Immuno-Oncology; Q3 Loss $3.5M, Cash $13.3M to End-2027
- Evaxion Refocuses on Cancer Vaccines as Q3 Loss Narrows to $3.5M, Cash Runway to Late 2027
- Evaxion's EVX-01 Achieves 89% Target Precision With Three-Year Durability
- EVX-01 Keeps Melanoma Patients Progression-Free at Three Years
- Evaxion Q2 Loss Narrows, ATM Sale Adds $1.5M, Cash Runway to H2 2027
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 27,571 shares in EVAX as of the October 30, 2026 settlement, a 58.9% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 59.5% of EVAX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for EVAX, detected from its recent SEC filings · based on capital-structure filings through 2026-09-04.
ATM Sales Quantified · Share Capital Increase
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
EVAX files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.